In conclusion, this expanded-access study provided T-DXd to patients with locally advanced or metastatic HER2-positive gastric and GEJ adenocarcinoma prior to marketing approval of T-DXd in Japan. This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.